Virax Biolabs Group Limited - VRAX

SEC FilingsOur VRAX Tweets

About Gravity Analytica

Recent News

  • 05.12.2025 - Chronic Illness and The Immune System: Chronic Illness and The Immune System: Could ViraxImmune™ Offer a Critical Diagnostic Breakthrough?
  • 04.28.2025 - Nigel McCracken, Virax COO, Discusses the New Frontier in Immune Diagnostics with The Scientist in This Innovation Spotlight.
  • 04.24.2025 - Virax COO, Nigel McCracken, Exaplains the Latest PAIS IVD Technolgy in His Latest PharmaExec.com Interview.
  • 04.24.2025 - Virax COO, Nigel McCracken, Exaplains the Latest PAIS IVD Technolgy in His Latest PharmaExec.com Interview.
  • 04.23.2025 - In His Latest PharmaExec.com Interview, Virax COO Nigel McCracken Shares New Insights Into the Link Between T Cell Exhaustion and Inflammation in Long-COVID.
  • 04.23.2025 - In His Latest PharmaExec Interview, Virax COO Dr Nigel McCracken Shares New Insights Into the Link Between T Cell Exhaustion and Inflammation in Long-COVID.
  • 04.17.2025 - Virax COO, Nigel McCracken, Discusses New Data on T Cell Exhaustion in Post-Acute Infection Syndromes with PharmExec.com in Latest Article.
  • 03.18.2025 - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
  • 03.18.2025 - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
  • 03.13.2025 - Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Recent Filings

  • 03.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 03.18.2025 - EX-99.1 EX-99.1
  • 03.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 03.13.2025 - EX-99.1 EX-99.1
  • 03.05.2025 - EX-99.1 EX-99.1
  • 03.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]